Abiomed Launches Impella Quality (IQ) Assurance Program and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Abiomed Launches Impella Quality (IQ) Assurance Program and Shares Insight From Largest Database of Real-World Evidence of High-Risk PCI and Cardiogenic Shock Patients

DANVERS, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Abiomed, Inc . (NASDAQ: ABMD ), a leading provider of breakthrough heart support and recovery technologies, announced today its Impella Quality (IQ) Assurance Program. The mission of the program is to improve real-world outcomes in Protected PCI and cardiogenic shock patients through training, education and utilization of clinical guidelines, protocols and best practices derived from observational quality assurance data (IQ), IRB approved registry data (cVAD) and IDE approved FDA studies.

These data resources include Abiomed’s IQ Database, which is a collection of observational quality assurance data on over 95% of Impella patients since the Impella 2.5™ heart pump’s introduction to the United States in 2008. Today, this holds more than 44,000 Impella case entries. This IQ database, combined with additional clinical data collected in the cVAD Registry™ and FDA pre- and post-market studies, has helped identify best practices and protocols that are linked to the highest survival and native heart recovery rates at the Impella hospitals. For example, the placement of Impella prior to doing a PCI in cardiogenic shock appears to improve outcomes.

We are sharing this with hospitals around the country as part of our comprehensive education and training initiatives with the goal of positively affecting both survival and recovery outcomes for this very high-risk patient population. Abiomed has invested more than $85 million in creating this collection of real-world evidence that is now being shared with our customers at no additional cost.

The goal of the IQ Program is to also complement these best practices with Abiomed’s clinical field team, consisting of over 250 individuals in the United States. This experienced team, which includes physicians and nurses, has expertise in hemodynamic support and provides 24x7 onsite clinical assistance from the cath lab to the Intensive Care Unit (ICU). The company also provides 24x7 call center support staffed by experienced cardiac nurses and technologists.  From an educational perspective, Abiomed has created case-based learning tools and reinforces guideline-based appropriate use treatment. The program also encourages the use of After Action Reviews, which is a continuous learning tool that hospital Heart Teams can implement to improve practices after each case. In addition, the appropriate use rationale includes seven society guidelines for the use of pVADs, supported by a compendium of resources on improved outcomes and cost effectiveness.

“Abiomed has created the largest high-risk PCI and cardiogenic shock database of real-world evidence with different levels of analysis from observational quality assessment, to IRB prospective registries, to FDA prospective randomized studies,” said Michael R. Minogue, Abiomed President, Chairman and Chief Executive Officer. “We believe that by sharing our data-driven insights and clinical expertise, we can help hospitals create protocols, processes, and best practices to improve outcomes in Protected PCI and cardiogenic shock around native heart recovery.”

ABOUT IMPELLA The Impella products offer the unique ability to stabilize the patient's hemodynamics and unload the heart, which allows the muscle to rest and potentially recover its native function.  Impella 2.5 received FDA PMA approval for high risk PCI in March 2015.  Impella 2.5, Impella CP, and Impella 5.0 received FDA PMA approval for cardiogenic shock in the setting of acute myocardial infarction/heart attack or after heart surgery. These are the first and only percutaneous temporary ventricular support devices that are FDA-approved as safe and effective for the cardiogenic shock indication. The Impella product portfolio, which is comprised of Impella 2.5, Impella CP, Impella 5.0, Impella LD, and Impella RP, has supported over 40,000 patients in the United States. 

The ABIOMED logo, ABIOMED, Impella, Impella CP, and Impella RP are registered trademarks of Abiomed, Inc. in the U.S.A. and certain foreign countries. Impella 2.5, Impella 5.0, Impella LD, and Protected PCI are trademarks of Abiomed, Inc.

ABOUT ABIOMED   Abiomed, Inc. based in Danvers, Massachusetts, is a leading provider of medical devices that provide circulatory support.  Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart.  For additional information, please visit:  www.abiomed.com .

FORWARD-LOOKING STATEMENTS   This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events. 

CONTACT: Adrienne Smith Senior Director, Corporate Communication & Public Relations 781-277-1170 adsmith@abiomed.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 466

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 223

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 335

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 246

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 185

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Geotab's Vision for Addressing Youth Unemployment Through Internships

Updated Category News Views 169

Geotab's Commitment to Future Workforce Development As Geotab Inc. celebrates its remarkable 25th anniversary, the company is taking bold steps to enhance internship opportunities for young graduates entering an increasingly competitive job market. With youth unemployment rates rising in North America, organizations like Geotab are not only addressing a pressing social...

Continue Reading
Joaquín de Valenzuela Joins nCino as EMEA Managing Director

Updated Category News Views 90

Joaquín de Valenzuela Takes the Helm at nCino for EMEA nCino, Inc. (NASDAQ: NCNO), a leader in intelligent banking solutions, is proud to announce the appointment of Joaquín de Valenzuela as the Managing Director for the EMEA region. This significant hire underscores the company's dedication to bolstering its growth trajectory and expanding its influence across the...

Continue Reading
Aya Gold & Silver Unveils Stunning Silver Drilling Results

Updated Category News Views 123

Aya Gold & Silver Reports New Silver Drilling Success Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) is excited to share outstanding silver drill results from its ongoing exploration at the Zgounder Silver Mine. The results not only highlight high-quality silver finds but also identify several promising new targets in the Zgounder Regional area. Drilling Highlights and...

Continue Reading
Nvidia's Deep Roots in China's Tech Landscape Drive AI Success

Updated Category News Views 278

Nvidia's Deep Roots in China's Tech Landscape Drive AI Success Nvidia Corp. CEO Jensen Huang recently highlighted the significant impact of China’s technology ecosystem on Nvidia’s growth during a keynote address at a major university event. His reflections underline a robust relationship spanning over 25 years, which has been pivotal in shaping Nvidia into a leading...

Continue Reading
Aalberts N.V. Achieves Strategic Growth Despite Market Challenges

Updated Category News Views 314

Aalberts N.V. Reports First Quarter Results In the latest financial report, Aalberts N.V. showcased its first quarter outcomes, revealing revenues of EUR 778.3 million. This figure marks a 3.3% decline in organic revenue compared to the same period last year, pointing to ongoing challenges within the market. Operational Performance and Margin Insights The company's EBITA...

Continue Reading